Investors are piling into BioNTech stock ahead of a pivotal fortnight for the German biotech. The share price surged more than five percent on Tuesday, closing at EUR 92.30, as the company confirmed its first-quarter report for May 5 and its Annual General Meeting for May 15. Trading volume was more than double the average, signaling deliberate buying interest rather than a technical move. The stock has now gained roughly 20 percent over the past month and sits above its 200-day moving average, a stark contrast to broader sector losses.
This rally is fueled by growing confidence in BioNTech’s expensive but deliberate pivot toward oncology. The company is navigating a significant transition year, with revenue expected to fall to between EUR 2.0 and 2.3 billion in 2026, down from nearly EUR 2.9 billion the prior year. The Q1 figures will offer the first concrete look at the financial impact of this shift following a net loss of EUR 1.14 billion for the full year 2025.
Financial stamina for this strategic overhaul is not in question. BioNTech entered the year with a formidable liquidity reserve of approximately EUR 17.2 billion. This war chest provides crucial breathing room as the company accelerates its clinical pipeline, aiming to reach late-stage trials across multiple programs by year-end. Data from seven key development programs are expected before 2026 concludes.
The virtual shareholder meeting on May 15 will formally reshape the company’s governance to support its new direction. A central proposal is to expand the supervisory board from six to eight members, adding two new specialists in oncology and clinical development. This structural change coincides with the search for successors to the founding duo, who plan to step back from operational roles by the end of the year.
Should investors sell immediately? Or is it worth buying BioNTech?
Shareholders will also vote on creating new authorized capital of up to EUR 129.5 million, equivalent to 50 percent of the current share capital. Another critical agenda item is the approval of a domination and profit transfer agreement with subsidiary BioNTech Discovery GmbH. This move aims to establish a tax group, allowing losses at the parent level to be offset against profits at the subsidiary—a vital financial mechanism given recent results.
Beyond the boardroom, the clinical pipeline is advancing rapidly. BioNTech is currently conducting 16 clinical trials in lung cancer, including four ongoing Phase 3 studies. With partner DualityBio, the company plans a potential FDA submission in 2026 for the antibody-drug conjugate Trastuzumab Pamirtecan, pending regulatory feedback. An application is already under review in China.
The twin events in May will define BioNTech’s path. The quarterly report will reveal the initial burn rate of its massive cash reserves, while the shareholder vote sets the legal, fiscal, and personnel foundation for its future as a dedicated oncology firm.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from April 22 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 22.
BioNTech: Buy or sell? Read more here...
